By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Advanced Cell OK’d to move forward with US trials
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Advanced Cell OK’d to move forward with US trials
Technology

Advanced Cell OK’d to move forward with US trials

HerinaAyot
HerinaAyot
Share
4 Min Read
SHARE

Advanced Cell Technology (OTCBB:ACTC) said Wednesday that it has received approval from the independent Data and Safety Monitoring Board to move forward with enrolling and treating the next set of patients in each of its two US stem cell clinical trials.

In July, surgeons treated the first patients in the company’s clinical trials for Stargardt’s Macular Dystrophy (SMD), a degenerative eye disease seen in young people, and Dry Age-Related Macular Degeneration (Dry AMD), a degenerative disease causing vision loss in older people.

Advanced Cell Technology (OTCBB:ACTC) said Wednesday that it has received approval from the independent Data and Safety Monitoring Board to move forward with enrolling and treating the next set of patients in each of its two US stem cell clinical trials.

In July, surgeons treated the first patients in the company’s clinical trials for Stargardt’s Macular Dystrophy (SMD), a degenerative eye disease seen in young people, and Dry Age-Related Macular Degeneration (Dry AMD), a degenerative disease causing vision loss in older people.

More Read

UM Life Science & Technology Park
Could Cultural Diversity Be the Key to Miami’s Life Science Boom?
How to Use Instagram Video in Healthcare
Evaluating and Choosing Healthcare Cloud Service Providers
Google Glass in Medicine: Why There Is Promise
‘Contact-Free’ Sensors May Hold the Key to Effective Patient Monitoring

In both cases, eventually, severe vision loss and even blindness results from photoreceptor loss associated with degeneration in a layer of the retina, called the retinal pigment epithelium (RPE).

The company’s treatment uses retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs), which can potentially be used to supply an unlimited amount of healthy RPE cells to treat degenerative retinal diseases.

Each patient received an injection of 50,000 hESC-derived RPE cells in one of their eyes. Both the Dry AMD and SMD clinical trials are dose-escalation studies involving twelve patients in each, and are designed to evaluate the safety and tolerability of the injected RPE cells.

The study design involves four cohorts of three patients, each being treated at a pre-determined dose of RPE cells, ranging from 50,000 to 200,000 cells.

Based on the results of the first patient in each study, the independent board authorized the company to move forward with the next two patients in the studies. Each of these additional patients will also be treated with 50,000 RPE cells, the company said.

“The unanimous recommendation of the DSMB to proceed with the next four patients represents a significant milestone for our clinical programs,” said chief scientific officer, Dr. Robert Lanza.

“We hope that the positive trend in clinical results derived from treating the first patients with our RPE cells will continue.”
Chairman and CEO of Advanced Cell, Gary Rabin, added: “The outcome of this in-depth safety review by an unbiased team of experts is very reassuring.

“The DSMB, which includes independent experts in macular degeneration, has recommended that the study continue at the present dosage of cells. We hope that in the near future we will be able to share both safety and physiological data we are continuing to obtain in these trials.”

Last week, the company announced that health authorities in the UK gave the go-ahead for its stem cell trials to treat patients with Stargardt’s, the first time such studies have been approved in Europe. The UK trials will begin in December at the prolific Moorfields Eye Hospital in London, the oldest and largest eye hospital in the world, under Professor James Bainbridge, consultant surgeon and Chair of Retinal Studies at University College London.- Deborah Sterescu

 

TAGGED:Advanced Cell TechnologyDry AMDSMDstem cells
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

IHT2 Summit in Seattle
BusinessTechnology

Adopting Technology in Healthcare for the Right Reasons

September 21, 2014
SpecialtiesTechnology

Types Of Equipment To Help You Stay Comfortable After Bariatric Surgery

April 18, 2019
eHealthMedical DevicesMedical InnovationsTechnology

How Artificial Intelligence is Merging With Diagnostic Imaging

October 4, 2017
BusinessTechnology

Tissue Engineering and Cell Therapy Market Growth

April 12, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?